Thomas Delaney - Board of Directors

Tom Delaney has over 25 years of experience working with start up life science and high tech companies.   He has served as Chief Financial Officer and at times has been responsible for sales and marketing, production, compliance and quality assurance.   Most recently Tom worked initially as CFO and then General Manager of International Sales for K2M, Inc., (Nasdaq: KTWO).   K2M is a medical device company focused on designing, developing and commercializing spinal implants.   Tom was CFO of GloboMax, LLC, a CRO specializing in FDA drug development, purchased by ICON (Nasdaq: ICON); Electric Press, Inc., an internet e-commerce and content management company purchased by NIC Commerce (Nasdaq: EGOV); CellCo, Inc., a cell and gene therapy research company, purchased by Spectrum Labs; ProScience, Inc., a developer of animal diagnostics; and Media Cybernetics, Inc., developers of image analysis software for life science.

Tom has  experience with raising funds from Venture Capital, Private Equity, and IPOs.   He has broad experience with the launch and development of Life Science companies.   Tom has a comprehensive understanding of Life Science product development  costs and timelines.  He has a unique perspective from his work with companies that provided drug development services and with companies who utilized these services.  Tom received his BBA from Wisconsin University and  started his career with Ernst and Young.